Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: p.G12C-mutated pancreatic cancer are unknown. METHODS: p.G12C-mutated pancreatic cancer who had received at least one previous systemic therapy. The primary objective of phase 1 was to assess safety and to identify the recommended dose for phase 2. In phase 2, patients received sotorasib at a dose of 960 mg orally once daily. The primary end point for phase 2 was a centrally confirmed objective response (defined as a complete or partial response). Efficacy end points were assessed in the pooled population from both phases and included objective response, duration of response, time to objective response, disease control (defined as an objective response or stable disease), progression-free survival, and overall survival. Safety was also assessed. RESULTS: The pooled population from phases 1 and 2 consisted of 38 patients, all of whom had metastatic disease at enrollment and had previously received chemotherapy. At baseline, patients had received a median of 2 lines (range, 1 to 8) of therapy previously. All 38 patients received sotorasib in the trial. A total of 8 patients had a centrally confirmed objective response (21%; 95% confidence interval [CI], 10 to 37). The median progression-free survival was 4.0 months (95% CI, 2.8 to 5.6), and the median overall survival was 6.9 months (95% CI, 5.0 to 9.1). Treatment-related adverse events of any grade were reported in 16 patients (42%); 6 patients (16%) had grade 3 adverse events. No treatment-related adverse events were fatal or led to treatment discontinuation. CONCLUSIONS: p.G12C-mutated advanced pancreatic cancer who had received previous treatment. (Funded by Amgen and others; CodeBreaK 100 ClinicalTrials.gov number, NCT03600883.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CodeBreaK100 (NCT03600883) clinical trial evaluated the safety and efficacy of sotorasib in advanced KRASG12C-mutant cancers, including 38 patients with metastatic, previously chemotherapy-treated PDAC. In these patients, a 21% objective response rate (ORR), a median progression-free survival (PFS) of 4.0 months, and a median overall survival (OS) of 6.9 months were observed (26).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [26]
In the citing paper
“For example, sotorasib, adagrasib, and divarasib monotherapies have demonstrated objective response rates ranging from 7.1% to 53.4% and median progression-free survival of 4.0-13.1 months, 13-20”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [16]
In the citing paper
“In the first published clinical series of KRASG12C inhibitor monotherapy in advanced PDAC, responses occurred in a minority of patients (~21%) and were generally transient75.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [75]
In the citing paper
“Even with recent advances in this space, currently only inhibitors targeting a specific KRAS mutation (KRAS G12C) have been FDA-approved in NSCLC (2–5).”
From Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors (2024) · cites this paper as [5]
In the citing paper
“Although recently developed KRAS G12C inhibitors, 10 including sotorasib and adagrasib, have shown antitumor activity in patients with previously treated KRAS G12C-mutated cancer, the extent of the clinical benefit remains limited, and better therapies to target KRAS G12C remain a high priority.[11][12][13][14][15][16][17][18]”
From Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation (2023) · cites this paper as [15]
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationDoebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Self-citation
Cited by
Items 401–500 of 579
Pancreatic Cancer: Translating Tumor Biology into Actionability
Balogun, F. O., Sherman, M. H., Park, W., Soares, K. C., Reyngold, M., Schoenfeld, J. D., Singhal, A., Iacobuzio–Donahue, C. A., & O'Reilly, E. M. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-2014 · Cited by 3
Wang, Y., Zhang, Y., Wang, X., Zhao, W., Li, Q., Zhou, M., Liu, Y., Yi, X., He, J. I., Li, Y. P., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02712-8 · Cited by 2
RAS signaling at the crossroads of radioresistance and tumor immunity
Quevrin, C., Mondini, M., Meziani, L., de Thoré, M. G., Liu, W., Lopes, E., Morel, D., Clémenson, C., Deutsch, É., & Lévy, A. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015274 · Cited by 1
Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges
Habib, R., Arnold, E., Obi, T., Vizeacoumar, F. J., & Ahmed, S. (2026) · Current Oncology · doi:10.3390/curroncol33080452 · Cited by 1
RAS Inhibitor RMC ‐7977 Blocks Vascular Overgrowth of NRAS Q61R Mutant Endothelial Cells
Alharbi, S., Merkle, S., Pastura, P. A., McDaniel, C. G., Zaky, G. S., Waters, A. M., & Cras, T. D. L. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71316 · Cited by 1
Kapoor, A., Sansar, B., Gupta, A., Mishra, B. K., Rungta, A., Pal, A., Srivastava, S., Shah, M. J., Menon, N. S., Pai, T., et al. (2026) · Medical Oncology · doi:10.1007/s12032-026-03318-2 · Cited by 2
KRAS and TP53 Circulating Tumor DNA are Prognostic in Localized Pancreatic Cancer
Sridalla, K., Vitello, D. J., Cox, M. C., Masnyk, L., Wells, A., Horowitz, A., Shah, D., Machhi, J. K., Rengaraju, V., Chibucos, A., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20447-0 · Cited by 1
Zielgerichtete Therapie des Pankreaskarzinoms
Witte, D. P., Dorman, K., Zhang, D., & Westphalen, C. B. (2023) · Die Onkologie · doi:10.1007/s00761-023-01385-y · Cited by 1
KRAS Wild-Type Pancreatic Cancer: Decoding Genomics, Unlocking Therapeutic Potential
Kato, H., Ellis, H., & Bardeesy, N. M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2221 · Cited by 1
Yang, S., Hua, Y., Liu, Q., & Liao, Q. (2024) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000172 · Cited by 1
The real-world management of advanced pancreatic cancer in China
Klotz, R., Michalski, C. W., & Kong, B. (2024) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000193 · Cited by 1
Characteristics of KRAS gene mutations in real clinical practice for pancreatic cancer
Manukyan, M. S., Bazin, I. S., & Tryakin, A. A. (2025) · Surgery and Oncology · doi:10.17650/2949-5857-2025-15-1-28-35 · Cited by 1
Fukuda, A., Mizuno, T., Yoshida, T., Sunami, K., Kubo, T., Koyama, T., Yonemori, K., Okusaka, T., Kato, K., Ohe, Y., et al. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf065 · Cited by 1
Li, Z., Wang, Z., Gan, H., Shen, F., Cheng, L.-S., & Zhang, X. (2025) · Future Science OA · doi:10.1080/20565623.2025.2532327 · Cited by 1
Bibliometric analysis of global research trends in pancreatic cancer immunotherapy
Fu, T., Chen, Y., Wang, H., He, L., Zhang, J., Zhou, Y., Duan, X., & Zhang, X. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2538330 · Cited by 1
GEMPAX, do we have another second-line option after mFOLFIRINOX in pancreatic cancer?
Boyle, K., & Perez, K. J. (2025) · Annals of Translational Medicine · doi:10.21037/atm-24-182 · Cited by 1
Lacalle-González, C., Lopez-Blazquez, C., Hidalgo-León, M. Á., Otieno, M. O., Sanz-Criado, L., Fernández‐Aceñero, M. J., Ortega, L. M., García‐Foncillas, J., & Martínez‐Useros, J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.12.675778 · Cited by 1
Mutant KRAS Suppresses DNA Sensing by Remodeling Membrane Tension to Clear Extracellular Tumor DNA
Cao, D., Zhou, W., Li, Z., Lu, S., Hou, Z., Yu, L., Guan, Y., Wang, G., Liu, Y., Huang, Z., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-4447
KRAS G12C mutation: from black sheep to key player in pancreatic cancer treatment
Ibrahim, R., Khoury, R., Ibrahim, T., Assi, T., & Cesne, A. L. (2023) · Future Oncology · doi:10.2217/fon-2023-0067
Personalized therapy in pancreatic cancer
Liberko, M., & Soumarová, R. (2023) · Onkologie · doi:10.36290/xon.2023.020
Aktuelle systemische Therapie beim Pankreaskarzinom
Springfeld, C., Krug, S., Neoptolemos, J. P., & Jäger, D. (2023) · Die Onkologie · doi:10.1007/s00761-023-01382-1
KRAS-G12C-Hemmung: potenzielle Option auch beim Pankreaskarzinom?
Klein, F. (2023) · Gastroenterologie up2date · doi:10.1055/a-2079-8920
Sionakidis, A., Lalagkas, P. N., Malousi, A., & Vizirianakis, I. S. (2023) · Clinical and Translational Discovery · doi:10.1002/ctd2.248
KRAS-G12C-Hemmung: potenzielle Option auch beim Pankreaskarzinom?
Klein, F. (2023) · TumorDiagnostik & Therapie · doi:10.1055/a-2193-1033
Updates of Chemotherapy for Pancreatic Cancer
Sung, M. J. (2023) · Journal of Digestive Cancer Research · doi:10.52927/jdcr.2023.11.3.147
Béchade, D., Palmieri, L., Bonhomme, B., Pernot, S., Léna, J., Fonck, M., Pesqué, S., Boillet, G., Italiano, A., & Roseau, G. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231224943
La médecine de précision dans le cancer du pancréas
Boilève, A. (2024) · theses.fr (ABES) · doi:10.70675/457b96a4z1192z4f54zbfd1z6e7250b130e3
Zielgerichtete Therapien in der gastrointestinalen Onkologie
Lange, S. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2060-2075
Neuerungen in der aktualisierten Leitlinie „Exokrines Pankreaskarzinom“
Kestler, A. M. R., & Seufferlein, T. T. W. (2024) · Forum · doi:10.1007/s12312-024-01326-9
Therapie des metastasierten Pankreaskarzinoms
Seufferlein, T. T. W., & Ettrich, T. J. (2024) · Springer Reference Medizin · doi:10.1007/978-3-642-54676-1_552-2
Zielgerichtete Therapie des Pankreaskarzinoms
Witte, D. P., Dorman, K., Zhang, D., & Westphalen, C. B. (2024) · Gastro-News · doi:10.1007/s15036-024-3709-5
Pankreaskarzinom und zystische Neoplasien im Pankreas
Kestler, A. M. R., & Seufferlein, T. T. W. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21011-2.00039-9
Misp53 mutation-specific oncogenic transcription factor complexes in PDAC progression
Urbach, L. (2024) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10588
Oscanoa, J., Ross‐Adams, H., Ullah, A. Z. M. D., Kolvekar, T. S., Sivapalan, L., Gadaleta, E., Thorn, G. J., Abdollahyan, M., Imrali, A., Saad, A. B., et al. (2024) · medRxiv · doi:10.1101/2024.07.25.24309825
Therapeutic Targeting of KRAS Oncogene in Pancreatic Ductal Adenocarcinoma (PDAC)
Song, J. J. (2024) · Journal of Student Research · doi:10.47611/jsrhs.v13i1.6375
Therapie des Pankreaskarzinoms: Innovative Chirurgie und moderne Systemtherapien
Hank, T. P., Springfeld, C., Loos, M., Zhou, X., Neoptolemos, J. P., Roth, S., Mehrabi, A., Michalski, C. W., Büchler, M. W., & Al‐Saeedi, M. (2024) · Deutsches Ärzteblatt · doi:10.3238/personko.2024.09.06.01
Immune-oncology potential of KRAS inhibitors
Molina‐Arcas, M., Boumelha, J., & Downward, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00013-9
Bravo, A. C., Morão, B., Luz, A., Dourado, R., Oliveira, B., Guedes, A., Moreira-Barbosa, C., Fidalgo, C. A., Mascarenhas‐Lemos, L., Costa-Santos, M. P., et al. (2024) · Cancers · doi:10.3390/cancers16203544
Advancements in Cancer Therapeutics: Emerging Agents and Combination Strategies in Drug Discovery
Hussain, A., & Hussain, A. (2025) · Clinical Cancer Drugs · doi:10.2174/012212697x361870250113043318
Evaluating Cancer Drug-Targeting Pathways with Large Language Models
Zhang, A., & Chen, J. Y. (2025) · doi:10.5121/csit.2025.150405
Diagnostik und Therapiekonzepte für das Pankreaskarzinom – Update 2024
Kestler, A. M. R., & Seufferlein, T. T. W. (2025) · Gastroenterologie up2date · doi:10.1055/a-2267-4079
Therapie des Pankreaskarzinoms: Innovative Chirurgie und moderne Systemtherapien
Hank, T. P., Springfeld, C., Loos, M., Zhou, X., Neoptolemos, J. P., Roth, S., Mehrabi, A., Michalski, C. W., Büchler, M. W., & MohamAl-Saeedi (2025) · Deutsches Ärzteblatt · doi:10.3238/persgastro.2025.04.04.02
Diagnostik und Therapiekonzepte für das Pankreaskarzinom – Update 2024
Kestler, A. M. R., & Seufferlein, T. T. W. (2025) · TumorDiagnostik & Therapie · doi:10.1055/a-2555-9348
Tumoral and circulating genomic landscape inform survival differences in colorectal carcinomatosis
White, M. G., Ayabe, R. I., Zeineddine, M. A. A., Zeineddine, F. A., Yousef, A. M. G., Yousef, M., Galbraith, N. J., Iorgulescu, J. B., Scally, C. P., Fournier, K. F., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102379
Wang, Y., Yusof, H. M., Aziz, M., & Chan, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-15609-0.00022-2
Pan-RAS inhibitor after KRASG12C treatment in pancreatic cancer?
Swales, L., Mathieu, J. R. R., Ducreux, M. P., Jaulin, F., & Boilève, A. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115588
Wang, Y., Geng, J., Gong, J., Li, Y., Liu, X., Sheng, W., & Zhen, Y. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107188
Maciel, D., Cope, S. F., Bouwmeester, W., Qian, C., Korytowsky, B., & Jansen, J. P. (2025) · Statistical Methods in Medical Research · doi:10.1177/09622802251354922
Hendi, M., Zhang, B., Mou, Y., & Cai, X.-J. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i7.103337
KRAS-driven pancreatic ductal adenocarcinoma cell lines harbour putative cancer stem cells
Teh, Y. H., Jing, R., Ramasamy, R., Ho, K. L., Sagineedu, S. R., & Stanslas, J. (2025) · ONCOLOGIE · doi:10.1515/oncologie-2025-0171
Adoptive T-Cell Therapy in Solid Tumor with KRASG12V/G12D MutationPreprint
Hu, H., Zeng, Z., Qin, T., Yu, G., Tsao, S.-T., Wu, L., Zhang, X., Gan, C., Jiang, X., Wu, X., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7496490/v1
Therapeutic pancreatic cancer biomarkers and pharmacogenetics
Langer, A., Souček, P., Vymetalkova, V., Rizzato, C., Bunduc, Ș., Nikas, I. P., Hlaváč, V., Kroupa, M., Farinella, R., Campa, D., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.08.002 · Cited by 1
Tumor nutrient stress gives rise to a drug tolerant cell state in pancreatic cancerPreprint
Sheehan, C. S., Hu, L., Cognet, G., Croley, G., Nguyen, T. T., Thomas-Toth, A. T., Agovino, D., Jonker, P. B., Sadullozoda, M., Ziolkowski, L. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.04.673818 · Cited by 1
Huang, F. J., & Huang, Z. (2025) · Journal of International Medical Research · doi:10.1177/03000605251388257
Future of Pancreatic Cancer Therapy: Getting Better, But not Good Enough Ye
Klose, J., Döbereiner, J., Sunami, Y., Rebelo, A., Ronellenfitsch, U., & Kleeff, J. H. (2025) · Archives of Medical Research · doi:10.1016/j.arcmed.2025.103336
Hubrecht, I., Friedrich, M., Liesenfeld, L. A., Barroux, M., Bendz, H., Maurer, H. C., Vielhauer, J., Lörsch, A. M., Jung, J., Schatz, U. A., et al. (2025) · Die Onkologie · doi:10.1007/s00761-025-01848-4
Khan, H. Y., Hallak, M. N. A., Aboukameel, A., Bannoura, S. F., Uddin, M. H., Aboukameel, A. A., Alkan, F. K., Çağlayan, A. B., Alkan, H. K., Bao, B., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.21.689857
Lin, J., Lin, Y., Cai, M., Chen, Y., Lin, X., Li, L., Lai, J., Huang, H., Li, J., Liu, Q., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114340
Mericoz, C. A., Kulaç, İ., Alper, E., Adsay, V. N., & Firat, P. (2025) · Acta Cytologica · doi:10.1159/000549794
Dreikhausen, L., Klupsch, A., Wiest, I., Xiao, Q., Schulte, N., Betge, J., Boch, T., Brochhausen, C., Gaiser, T., Hofheinz, R.-D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26712305
Pernerstorfer, J. (2023) · Open access LMU (Ludwid Maxmilian's Universitat Munchen) · doi:10.5282/ubm/epub.107258
Dang, S., Zhang, S., Zhao, J., & Li, W. (2024) · Figshare · doi:10.6084/m9.figshare.26308921
Understanding Drug Synergy in Pancreatic Cancer: A Proteomic Study of Gemcitabine and ATR Inhibitors
Höfer, S., Küster, B., & München, T. U. (2024)
Two Strategies for Targeting the LRRK2 GTPase
Zhu, L. (2023) · eScholarship (California Digital Library)
Fabregat-Franco, C. (2025) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Computational Evaluation of the Inhibitory Potential of Phytochemical Compounds on the KRAS Protein
Aydın, G. (2025) · Ordu Üniversitesi Bilim ve Teknoloji Dergisi · doi:10.54370/ordubtd.1809849
Barreto, S. G., Loveday, B. P. T., Mittal, A., Pandanaboyana, S., & Windsor, J. A. (2026) · Digestive Surgery · doi:10.1159/000550333
Hollander, E. M., Buma, A. I. G., Leentjens, J., Janssen, P. K. C., van den Heuvel, M. M., Burger, D. M., Piet, B., & ter Heine, R. (2026) · International Journal of Cancer · doi:10.1002/ijc.70326
Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma
Nallasamy, P., Seshacharyulu, P., Rauth, S., Shah, A., Marimuthu, S., Varadharaj, V., Bommideni, M., Mallya, K. B., Alsafwani, Z. W., Lele, S. M., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218276
CEP55 Drives Pancreatic Cancer Progression by Suppressing Ferroptosis
Zhang, S., Chai, J., Zhang, W., & Hu, M. (2026) · BioFactors · doi:10.1002/biof.70084
Akiyama, R., Kawashita, Y., Ochiai, M., Tateishi, M., Ueda, T., Nakamura, M., Umeda, K., Harada, S., Abe, S., Haraguchi, M., et al. (2026) · Cureus · doi:10.7759/cureus.103628
Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors
Kanemura, H., Takehara, T., Maenishi, O., Tomida, S., Iwawaki, N., Kunimasa, K., Nakayama, T., Watanabe, S., Suzuki, S., Sakai, K., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0489
The Tumour, the Host and Chemotherapy Response in Pancreatic Cancer
Svensson, M. (2026) · Lund University Publications (Lund University)
Yang, J., Chen, W., Duan, Z., Yang, M., Tao, L., Huo, Y., Liu, W., Zhang, J., Yao, L., Liu, Y., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3359 · Cited by 1
Recent Advancements in Diagnosis and Targeted Therapy of Pancreatic Cancer
Patil, J., & Kanugo, A. (2026) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206429348260126061757
Du, F., George, T. J., Guo, Y. M., Khosrow‐Khavar, F., Liu, Q., Perkins, C. M., Jiang, J., DeRemer, D. L., McDonough, C. W., Lian, Y., et al. (2026) · International Journal of Cancer · doi:10.1002/ijc.70438
Self-citationKwok, G. W., Lo, J., & Fung, T. H. W. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70353
Yang, B., Liu, X., Wei, J., Xu, L., Zhang, J., Fan, M., Hou, Y., Zhang, F., Chen, Y., Liu, W., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218452
Innovative targeted therapies for mosaic RAS-related vascular malformations
Morin, G. (2024) · theses.fr (ABES) · doi:10.70675/88882e5fz1bf9z4dbezae13zba4200ee9598
PrimO-3D : a pancreatic carcinogenesis model for translational research and drug testing
Miri, J. (2024) · theses.fr (ABES) · doi:10.70675/e86d07bbza1f0z4ebazacafz78d9b1ac2654
Dialogue entre tumeur pancréatique et son tissu adjacent : une relation sous pression
Lac, C. (2024) · theses.fr (ABES) · doi:10.70675/2d1f2e5azea41z4ce5z8bd8z556728461640
Yu, Y.-N., Jin, S.-Q., Lu, Y.-T., & Han, L.-Z. (2026) · World Journal of Clinical Oncology · doi:10.5306/wjco.v17.i4.117197
Zivic, T. (2026) · Repository of the University of Ljubljana (University of Ljubljana)
Nishio, M., Sugiyama, H., McCormack, V., Viguier, J., Quesnel, B., Iovanna, J., Dusetti, N., Hammel, P. R., Henrion, M. C., Monge, C., et al. (2026) · JCO Global Oncology · doi:10.1200/go-25-00483
Zhu, G., Pei, L., Li, J., Zhang, C., Ye, D., Li, J., Tang, Q., Huang, H., Xu, H., & Bi, F. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117338
German, A. N., & Ocuin, L. M. (2026) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2026.102449
Targeting KRAS G12C in Rare Mesonephric Carcinoma of the Cervix: A Promising Response to Sotorasib
Li, B. C. W., Li, J. J. X., Tse, K. Y., Lu, H., & Chan, K. K. L. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01077
王, 小. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1651820
Awn, A. K., Arean, A. G., Findakly, S. B., Yasin, Y. S., & Jumaa, A. H. (2026) · Asian Pacific Journal of Cancer Biology · doi:10.31557/apjcb.2026.11.1.9-22
Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies
Hue, J. J., Zarei, M., Sunita, P., Abul-Khoudoud, S. O., Dey, G., Graor, H. J., Blise, K. E., Keith, D., Sivagnanam, S., Pattanayak, S. P., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0338
Lefas, A. Y., Lote, H., & Chau, I. (2026) · Precision Oncology · doi:10.3390/precisoncol1020009
Li, Y., Zhou, M., Pan, J., Su, H., Song, M., Guan, Z., Zhao, D., Zhao, X., Zhao, Y., Chen, P., et al. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102821
Hernandez, S., & Maker, A. V. (2026) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-2025-1-952
Piejko, M., Bak, K., Wierciak, J., Plutecka, H., Wilczyńska-Zawal, N., Osmola, M., Rapacz, K., Kijowski, J., Mensah‐Glanowska, P., Szczepanik, A., et al. (2026) · Cancers · doi:10.3390/cancers18111852
Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRASG12C inhibitors
Zhu, Y., Zhang, C., Li, M., Ai, L., Xu, F., Yu, Y., Yu, S., Xu, X., Liu, Q., Zhu, M., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03838-1
Kızıl, H. E., Ekíncíoğlu, Y., Özkan, E. H., Güllü, E., & Nartop, D. (2026) · Discover Chemistry. · doi:10.1007/s44371-026-00785-4
Hsu, F.-C., Pu, T., Lin, J.-C., & Chen, C. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102872
Gesamtüberleben verlängert – aber um wie lang?
Borchers, M., & Klein, F. (2026) · Gastro-News · doi:10.1007/s15036-026-4067-2
Actualités dans le traitement médical des adénocarcinomes pancréatiques
Rémond, M., & Coriat, R. (2026) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2026.100825 · Cited by 1
Metadata
- Authors
- Strickler, J. H., Satake, H., George, T. J., Yaeger, R., Hollebecque, A., Garrido-Laguna, I., Schuler, M., Burns, T. F., Coveler, A. L., Falchook, G. S., Vincent, M., Sunakawa, Y., Dahan, L., Bajor, D., Rha, S.-Y., Lemech, C., Juric, D., Rehn, M., Ngarmchamnanrith, G., Jafarinasabian, P., Tran, Q., & Hong, D. S.
- Affiliations
- Kansai Medical University (JP)
- From Duke University Medical Center, Durham, NC (J.H.S.); Kansai Medical University, Shinmachi, Hirakata (H.S.), and St. Marianna University School of Medicine, Kawasaki (Y.S.) — both in Japan; University of Florida, Gainesville (T.J.G.); Memorial Sloan Kettering Cancer Center, New York (R.Y.); Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif (A.H.), and Marseille University Hospital, Marseille (L.D.) — both in France; Huntsman Cancer Institute, University of Utah, Salt Lake City (I.G.-L.); West German Cancer Center, University Hospital Essen, Essen (M.S.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (T.F.B.); Fred Hutchinson Cancer Center, University of Washington, Seattle (A.L.C.); Sarah Cannon Research Institute at HealthONE, Denver (G.S.F.); London Regional Cancer Program, London, ON, Canada (M.V.); University Hospitals Cleveland Medical Center, Cleveland (D.B.); Yonsei Cancer Center, Seoul, South Korea (S.-Y.R.); Scientia Clinical Research and Prince of Wa...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-05
- Volume
- 388
- Issue
- 1
- Pages
- 33-43
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10506456
- OpenAlex
- W4312094134
- Semantic Scholar
- 488922b069e36918a499827187276c02b891cb58
- Cited by
- 527
- References
- 34
- Citations by year
- 2026: 138 · 2025: 169 · 2024: 142 · 2023: 78
- FWCI
- 40.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Amgen Inc.
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- sotorasib, KRAS G12C mutation, advanced pancreatic cancer, KRAS inhibitors, metastatic pancreatic cancer, previously treated patients, objective response, progression-free survival, overall survival, treatment safety, adverse events
- MeSH terms
- Immune Checkpoint Inhibitors, Administration, Oral, Humans, Lung Neoplasms, Mutation, Pancreatic Neoplasms, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras), Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.